News
CAMBRIDGE, Mass., Nov. 29, 2022 /PRNewswire/ — Rgenta Therapeutics Inc. announced today that it closed a $52 million Series A round led by AZ-CICC Healthcare Investment Fund with participation from all existing investors and new investors including Korean Investment Partners, Delos Capital. Rgenta Therapeutics is focusing on developing RNA-targeting medicines for historically undruggable disease targets. Read more …
Cambridge, MA biotech Rgenta Therapeutics has secured $52 million in a Series A to take oral small molecules into the clinic.
The 20-person biotech, which is already allied with Lundbeck, looks to ink more pharma partnerships within its core areas of oncology and neuroscience rare diseases, as well as in other disease areas the startup thinks the RNA-targeting platform can go, CSO Travis Wager told Endpoints News ahead of the Tuesday morning news. Read more …
CAMBRIDGE, Mass., Aug. 4, 2021 /PRNewswire/ — Rgenta Therapeutics, Inc., announced today a strategic R&D collaboration with H. Lundbeck A/S aimed at the discovery of small molecules targeting RNA regulation and splicing of disease-causing genes for neurological disorders. Read more…
After selling off a discarded Alzheimer’s disease drug last month, Lundbeck is bulking up its neurological R&D through a $10 million pact with the relatively unknown small biotech Rgenta Therapeutics. Read more …..
CAMBRIDGE, Mass., May 25, 2021 — Rgenta Therapeutics announced today that it closed an $18 million seed extension round and welcomed Lilly Asia Venture (LAV) and Vivo Capital as new investors to the syndicate. Rgenta Therapeutics is focusing on developing RNA-targeting medicines for historically undruggable disease targets. Read more…..
CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ — Rgenta Therapeutics announced today that it closed an $18 million seed extension round and welcomed Lilly Asia Venture (LAV) and Vivo Capital as new investors to the syndicate. Rgenta Therapeutics is focusing on developing RNA-targeting medicines for historically undruggable disease targets. Read more …
CAMBRIDGE, Mass., May 25, 2021 — Rgenta Therapeutics announced today that it closed an $18 million seed extension round and welcomed Lilly Asia Venture (LAV) and Vivo Capital as new investors to the syndicate. Rgenta Therapeutics is focusing on developing RNA-targeting medicines for historically undruggable disease targets. Read more…..